# Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers

> **NCT02253823** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 68 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** EFV
- **DRUG:** TPV/RTV - low dose
- **DRUG:** TPV/RTV - high dose

## Key facts

- **NCT ID:** NCT02253823
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2002-03
- **Final completion:** —
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2014-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02253823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02253823, "Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02253823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*